Fresenius SE & Co. KGaA Stock Forecast for 2023 - 2025 - 2030
Updated on 03/27/2024
Fresenius SE & Co. KGaA Stock Forecast and Price Target
The average price target for Fresenius SE & Co. KGaA's stock of 35.00€ recently provided by six leading analysts would represent a 37.42% upside from its last closing price if reached. This potential increase is based on a high estimate of 70.00€ and a low estimate of 28.00€. If you are looking to invest in the stock, it's important to research and compare different companies.
37.42% Upside
Fresenius SE & Co. KGaA Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Fresenius SE & Co. KGaA's Price has seen a drop from 39.45€ to 0.00€ – a 100.00% decrease. In the next year, analysts predict that Fair Value will jump to 37.73€ – up 100.00% from the current level. Looking ahead to seven years, experts forecast that Fair Value will grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$734.37 | Buy/Sell | $636.99 | 10.71% |
NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
12
|
kr895.10 | Buy/Sell | kr696.07 | 6.13% |
MRK Stock Forecast | Merck | Outperform |
2
|
$122.77 | Buy/Sell | $130.51 | 9.96% |
NESN Stock Forecast | Nestlé | Outperform |
11
|
CHF93.99 | Buy/Sell | CHF115.58 | 16.50% |
ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF242.00 | Buy/Sell | CHF307.83 | 11.57% |
Fresenius SE & Co. KGaA Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Fresenius SE & Co. KGaA's Revenue has grown, moving from 36.28€B to 40.84€B – an increase of 12.58%. According to 4 major analysts, Fresenius SE & Co. KGaA's Revenue will fall by 29.35% in the next year, reaching 28.85€B. Professionals believe that By 2030, Fresenius SE & Co. KGaA's Revenue will fall to 28.43€B– a 30.38% decrease from its current value.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$120.19 | Buy/Sell | $118.92 | 4.83% |
AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£104.50 | Buy/Sell | £165.99 | 53.79% |
NOVN Stock Forecast | Novartis | Outperform |
10
|
CHF88.80 | Buy/Sell | CHF105.00 | 23.95% |
Fresenius SE & Co. KGaA Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Fresenius SE & Co. KGaA's Dividend per Share has seen an increase, rising from 0.88€ to 0.92€. This represents a growth of 4.55%. Analysts predict that Fresenius SE & Co. KGaA's Dividend per Share will increase in the upcoming year, reaching 1.02€. This would represent an increase of 10.87%. Over the next seven years, experts predict that Fresenius SE & Co. KGaA's Dividend per Share will grow at a rate of 47.83%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.37 | Buy/Sell | $32.87 | 10.82% |
SAN Stock Forecast | Sanofi | Outperform |
16
|
88.32€ | Buy/Sell | 102.80€ | 21.15% |
GSK Stock Forecast | GSK | Outperform |
12
|
£16.75 | Buy/Sell | £17.30 | 11.04% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$239.50 | Buy/Sell | $284.47 | 16.91% |
SUNPHARMA Stock Forecast | Sun Pharmaceutical Industries | Outperform |
8
|
Rp1.59k | Buy/Sell | Rp1.52k | -1.42% |
BN Stock Forecast | Danone | Outperform |
11
|
58.97€ | Buy/Sell | 55.47€ | 8.53% |
Fresenius SE & Co. KGaA EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Fresenius SE & Co. KGaA's EBITDA has decreased from 6.17€B to 5.07€B – a 17.82% drop. In the coming year, analysts are expecting an increase in EBITDA, predicting it will reach 5.39€B – an increase of 6.26%. Over the next seven years, experts anticipate that EBITDA growth for Fresenius SE & Co. KGaA will be 0.01%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
4543 Stock Forecast | Terumo | Outperform |
18
|
¥5.63k | Buy/Sell | ¥4.97k | -9.46% |
BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$43.48 | Buy/Sell | $44.86 | 3.50% |
500124 Stock Forecast | Dr. Reddy's Laboratories | Hold |
18
|
Rp6.38k | Buy/Sell | Rp5.67k | -6.20% |
Fresenius SE & Co. KGaA EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Fresenius SE & Co. KGaA's EBIT has decreased by 24.68%, going from 4.47€B to 3.37€B. 3 analysts predict Fresenius SE & Co. KGaA's EBIT will decrease by 6.57% in the next year, reaching 3.15€B. For the next seven years, the forecast is for EBIT to grow by 28.85%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£19.10 | Buy/Sell | £28.11 | 55.34% |
002422 Stock Forecast | Sichuan Kelun Pharmaceutical | Outperform |
16
|
¥27.85 | Buy/Sell | ¥37.90 | 43.63% |
GRF Stock Forecast | Grifols | Outperform |
18
|
8.48€ | Buy/Sell | 18.48€ | 116.98% |
Fresenius SE & Co. KGaA EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Fresenius SE & Co. KGaA's EPS has seen a drop from 3.22€ to 0.00€ – a 100.00% decrease. In the next year, analysts predict that EPS will jump to 3.08€ – up 100.00% from the current level. Looking ahead to seven years, experts forecast that EPS will grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$30.59 | Buy/Sell | $44.75 | 27.49% |
HAE Stock Forecast | Haemonetics | Outperform |
16
|
$78.36 | Buy/Sell | $70.17 | 38.46% |
BHC Stock Forecast | Bausch Health Companies | Hold |
15
|
$9.12 | Buy/Sell | $9.50 | -1.32% |